China NT Pharma Group Company Limited

1011

KYG2114L1133

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-07-02 am EDT			5-day change	1st Jan Change
0.034 ^HKD	-90.29%		-90.68%	-93.82%

Jun. 07	China NT Pharma Shareholders to Vote June 28 on Proposed Share Consolidation	MT
May. 29	China NT Pharma Group Company Limited Announces Change of Address of the Principal Place of Business and Headquarters	CI

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about China NT Pharma Group Company Limited

China NT Pharma Shareholders to Vote June 28 on Proposed Share Consolidation	Jun. 07	MT
China NT Pharma Group Company Limited Announces Change of Address of the Principal Place of Business and Headquarters	May. 29	CI
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
China NT Pharma Group Company Limited Announces Directorate Changes	Jan. 15	CI
China NT Pharma Group Company Limited Announces Change of Company Secretary, Effective 31 December 2023	Dec. 29	CI
China NT Pharma Group, Private Equity Fund Sign Cooperation Agreement; Shares Rise 4%	23-10-09	MT
China NT Pharma Raises HK$13 Million from Private Placement	23-09-22	MT
NT Pharma Seeks Nearly HK$24 Million from Share Placement	23-09-04	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
China NT Pharma Lays Out Restructuring Plan for Embattled Unit Suzhou First Pharma	23-07-27	MT
China NT Pharma Unit Faces Lawsuits for Alleged Loan Default	23-05-02	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
China Nt Pharma Group Company Limited Announces Change of Independent Non-Executive Director and Member of Audit Committee	23-01-19	CI
Konruns Pharma Cancels Osteoporosis Drug Agreement With NT Pharma, US-based Pfenex	22-12-20	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
China NT Pharma Group Company Limited Announces Resignation of Wu Weizhong as Executive Director and Senior Vice President	22-08-24	CI
China NT Pharma Signs Licensing Deal with US Company for Antibody Products	22-06-14	MT
China NT Pharma Group Company Limited Intends to Set Up A Joint Venture Company	22-05-17	CI
China NT Pharma Group Company Limited Updates on Delay in Publication of Audited Annual Results for the Year Ended 31 December 2021	22-04-04	CI
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
China NT Pharma : Narrows H1 Loss on Increased Antipsychotic Drug Sales	21-09-01	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-31	CI
China NT Pharma : NT Pharma to Narrow Loss, Increase Revenue in H1	21-08-30	MT
China NT Pharma Group Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2021	21-08-27	CI
Fortune Blaze Investments Limited completed the acquisition of The Mountains Limited from China NT Pharma Group Company Limited.	21-06-01	CI

Chart China NT Pharma Group Company Limited

Duration

Period

Chart China NT Pharma Group Company Limited

More charts

China NT Pharma Group Co Ltd is an investment holding company principally engaged in the research and development, production and sales of pharmaceutical products. The Company mainly provides development, distribution and agency services for sales of proprietary pharmaceutical products. The Company operates its bone health digital medicine platform by providing customized health package including bone health products, equipment and rehabilitation products. In addition, the Company engages in the investment in drugs and pharmaceutical companiesâ equity as well as provision of marketing and promotion services to suppliers.

Sector

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company